Pathologic Responses Result From Neoadjuvant SBRT Plus Cemiplimab in Resectable HCC

Press/Media

Period11 Jan 2024

Media coverage

1

Media coverage

  • TitlePathologic Responses Result From Neoadjuvant SBRT Plus Cemiplimab in Resectable HCC
    Media name/outletOncology Nursing News
    Country/TerritoryUnited States
    Date11/01/24
    PersonsThomas Marron
View all 1
View less